Pfizer, BioNTech’s Covid-19 vaccine expected to be ready for approval by year end: Report

By: |
July 10, 2020 6:43 PM

Covid-19 vaccine: The experimental vaccine, which showed promise against the fast-spreading respiratory illness in early stage human testing, is expected to move into a large trial involving 30,000 healthy participants later this month, pending regulatory nod.

Several hundred million doses could be produced even before the approval. (Reuters)

BioNTech SE and Pfizer Inc’s COVID-19 vaccine candidate is expected to be ready to seek regulatory approval by the end of 2020, the Wall Street Journal reported on Friday, citing the German biotech firm’s chief executive officer.

The experimental vaccine, which showed promise against the fast-spreading respiratory illness in early stage human testing, is expected to move into a large trial involving 30,000 healthy participants later this month, pending regulatory nod.

If it receives marketing approval, the companies are preparing to make up to 100 million doses by the end of 2020 and another 1.2 billion doses by the end of 2021 at sites in Germany and the United States, Reuters reported last week.

Several hundred million doses could be produced even before the approval, according to the WSJ report.

BioNTech and Pfizer did not immediately respond to Reuters’ request for comment.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1COVID-19 India vaccine: Going for vaccination is personal decision, people’s confidence will get boosted slowly, says Satyendar Jain
2Number of people vaccinated against COVID-19 more than double number of active cases: Govt
3Covid-19 Vaccine India update: Bharat Biotech, SII issue factsheets for Covaxin, Covishield; experts question Centre’s role